Biocon launches ALZUMAb for psoriasis patients in India

Biocon, Asia's premier biotechnology company, today announced the launch of its first in class novel biologic ALZUMAb (Itolizumab), the world’s first anti-CD6 monoclonal antibody to be introduced for treating patients with chronic plaque psoriasis, in India.

 ALZUMAb with a unique Mechanism of Action (MOA) offers superior safety and similar efficacy profile compared to other existing therapies, and has a long remission period with very low opportunistic infection rate. Psoriasis is a socially debilitating disease affecting 2-3 percent of world population